Table 1.

Summary of ongoing clinical trials targeting IL-33 pathway in COPD and asthma.

Condition	Intervention	ClinicalTrials.gov identifier	Comparison	Phase
COPD	Anti-IL-33 monoclonal antibody	NCT03546907	Placebo	2
COPD	Anti-ST2 antibody	NCT03615040	Placebo	2
Asthma	Anti-IL-33 receptor monoclonal antibody	NCT03207243	Placebo/fluticasone propionate with salmeterol/ fluticasone propionate	2
Asthma	Anti-IL-33 monoclonal antibody	NCT03112577	Placebo/Dupilumab/ anti-IL-33 antibody with Dupilumab/fluticasone propionate	1